Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.LONA · Entity 1487 | Director | June 23, 2026 | June 24, 2026 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director · CHIEF EXECUTIVE OFFICER | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2036-06-22 | Direct | 28,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 28,000 · Balance 28,000 F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Vaxcyte, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 429,902 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 17,056 · Balance 429,902 F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 133,215 F2: Shares are held directly by a trust for the benefit of the Reporting Person's son. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 133,215 F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Shares are held directly by a trust for the benefit of the Reporting Person's son.
F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2023 Filed Nov 3, 2023 20:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3 | $48.10 | $144.30 |
DisclosureSEC source: 0001209191-23-054326 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 153,903 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,306 | $47.27 | $61,734.62 |
DisclosureSEC source: 0001209191-23-054326 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 153,906 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $47.00 to $47.77. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3 | $48.10 | $144.30 |
DisclosureSEC source: 0001209191-23-054326 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 153,903 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,306 | $47.31 | $61,789.47 |
DisclosureSEC source: 0001209191-23-054326 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 153,906 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $47.005 to $47.815. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| October 23, 2023 Filed Oct 25, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,764 | $47.35 | $178,214.11 |
DisclosureSEC source: 0001209191-23-053545 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 385,914 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $47.25 to $47.58. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 23, 2023 Filed Oct 25, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 11,236 | $46.98 | $527,856.04 |
DisclosureSEC source: 0001209191-23-053545 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,678 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $46.255 to $47.245. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 442 | $51.55 | $22,785.10 |
DisclosureSEC source: 0001209191-23-051894 · doc4.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 155,212 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F9 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $51.39 to $51.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 221 | $50.48 | $11,156.08 |
DisclosureSEC source: 0001209191-23-051894 · doc4.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 155,654 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F8 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $50.31 to $50.064. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 646 | $49.68 | $32,093.28 |
DisclosureSEC source: 0001209191-23-051894 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 155,875 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $49.195 to $50.025. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 283 | $51.52 | $14,580.16 |
DisclosureSEC source: 0001209191-23-051894 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 155,212 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $51.505 to $51.565. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 385 | $50.76 | $19,542.60 |
DisclosureSEC source: 0001209191-23-051894 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 155,495 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $50.31 to $51.245. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 641 | $49.67 | $31,838.47 |
DisclosureSEC source: 0001209191-23-051894 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 155,880 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $49.205 to $50.025. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 20:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,309 | $52.44 | $68,640.69 |
DisclosureSEC source: 0001209191-23-050662 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 156,521 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $51.96 to $52.635. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 20:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,309 | $52.42 | $68,623.41 |
DisclosureSEC source: 0001209191-23-050662 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 156,521 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $51.96 to $52.605. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F4 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 20:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 15,000 | $52.45 | $786,793.50 |
DisclosureSEC source: 0001209191-23-050662 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400,914 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $51.695 to $52.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 10,378 | $51.00 | $529,278.00 |
DisclosureSEC source: 0001209191-23-048465 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,914 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. F2 · balance_after: Includes 1,040 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2023. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:56 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-23-031554 · doc4.xml · derivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires 2033-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 19, 2024, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 19, 2023. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Read SEC document |
| March 30, 2023 Filed Mar 31, 2023 20:36 UTC | LeonaBio, Inc. ATHA · Entity 1487 | PurchaseCommon Stock | 15,000 | $2.47 | $37,050.00 |
DisclosureSEC source: 0001209191-23-021878 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,783 F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.42 to $2.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:36 UTC | LeonaBio, Inc. ATHA · Entity 1487 | PurchaseCommon Stock | 10,000 | $2.33 | $23,300.00 |
DisclosureSEC source: 0001209191-23-021878 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,783 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.26 to $2.34, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 22:09 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 3,099 | $41.49 | $128,577.51 |
DisclosureSEC source: 0001209191-23-015712 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,252 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:09 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 323,250 | $0.00 Strike: $41.67 | $0.00 |
DisclosureSEC source: 0001209191-23-015712 · doc4.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,250 Underlying: Common Stock · 323,250 shares Expires 2033-03-01 F5 · derivative.exercise_date: 1/48 of shares subject to the option vest on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:09 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 53,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015712 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,351 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2023 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,158 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-23-000943 · doc4.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,227 Underlying: Common Stock · 15,158 shares Expires 2028-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 108,250 | $0.00 Strike: $47.95 | $0.00 |
DisclosureSEC source: 0001209191-23-000943 · doc4.xml · derivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,250 Underlying: Common Stock · 108,250 shares Expires 2032-12-30 F3 · derivative.exercise_date: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,158 | $2.03 | $30,770.74 |
DisclosureSEC source: 0001209191-23-000943 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 22:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 319 | $25.28 | $8,064.64 |
DisclosureSEC source: 0001209191-22-051492 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Children's Trust Disclosed balance after: 157,830 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.25 to $25.34. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 22:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,681 | $24.68 | $115,508.36 |
DisclosureSEC source: 0001209191-22-051492 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Children's Trust Disclosed balance after: 158,149 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.23 to $25.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 22:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 227 | $25.30 | $5,742.87 |
DisclosureSEC source: 0001209191-22-051492 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Children's Trust Disclosed balance after: 157,830 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.26 to $25.34. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 22:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,773 | $24.69 | $117,831.05 |
DisclosureSEC source: 0001209191-22-051492 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Children's Trust Disclosed balance after: 158,057 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.215 to $25.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 11,000 | $27.95 | $307,412.60 |
DisclosureSEC source: 0001209191-22-050527 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,546 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $27.64 to $28.56. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 20:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 8,910 | $26.38 | $235,045.80 |
DisclosureSEC source: 0001209191-22-049020 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 663,546 F1 · kind: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| August 26, 2022 Filed Aug 30, 2022 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 15 | $28.00 | $420.00 |
DisclosureSEC source: 0001209191-22-047991 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Children's Trust Disclosed balance after: 162,830 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| August 26, 2022 Filed Aug 30, 2022 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,985 | $27.44 | $136,788.40 |
DisclosureSEC source: 0001209191-22-047991 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Children's Trust Disclosed balance after: 162,845 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.91 to $27.785. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| August 26, 2022 Filed Aug 30, 2022 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 14 | $28.00 | $392.00 |
DisclosureSEC source: 0001209191-22-047991 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Children's Trust Disclosed balance after: 162,830 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| August 26, 2022 Filed Aug 30, 2022 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,986 | $27.44 | $136,815.84 |
DisclosureSEC source: 0001209191-22-047991 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Children's Trust Disclosed balance after: 162,844 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.88 to $27.875. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 608 | $26.30 | $15,990.40 |
DisclosureSEC source: 0001209191-22-046392 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,456 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.22 to $26.33. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10,392 | $25.54 | $265,411.68 |
DisclosureSEC source: 0001209191-22-046392 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 673,064 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.21 to $26.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 26, 2022 Filed Jul 28, 2022 21:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,000 | $23.27 | $116,353.00 |
DisclosureSEC source: 0001209191-22-043395 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Children's Trust Disclosed balance after: 167,830 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.965 to $23.79. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| July 26, 2022 Filed Jul 28, 2022 21:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,000 | $23.26 | $116,310.50 |
DisclosureSEC source: 0001209191-22-043395 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Children's Trust Disclosed balance after: 167,830 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.99 to $23.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 21:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,680 | $24.88 | $66,678.40 |
DisclosureSEC source: 0001209191-22-042603 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 683,456 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 21:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 8,320 | $24.34 | $202,508.80 |
DisclosureSEC source: 0001209191-22-042603 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,136 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $23.88 to $24.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 28, 2022 Filed Jun 28, 2022 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10,000 | $21.00 | $210,000.00 |
DisclosureSEC source: 0001209191-22-039646 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Children's Trusts Disclosed balance after: 345,660 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 747 | $21.01 | $15,696.26 |
DisclosureSEC source: 0001209191-22-039646 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694,456 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $21.00 to $21.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 23, 2022 Filed Jun 23, 2022 21:48 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,541 | $21.01 | $74,410.22 |
DisclosureSEC source: 0001209191-22-039044 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,203 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $21.00 to $21.09. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 21:48 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,261 | $21.01 | $26,492.22 |
DisclosureSEC source: 0001209191-22-039044 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,744 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $21.00 to $21.065. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 21:48 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,451 | $21.05 | $114,736.46 |
DisclosureSEC source: 0001209191-22-039044 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,005 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $21.00 to $21.31. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,562 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 17, 2022. Read SEC document |
| May 20, 2022 Filed May 27, 2022 21:51 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 3,467 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001209191-22-032699 · doc4.xml · derivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,467 Underlying: Common Stock · 3,467 shares Expires 2032-05-19 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-22-030067 · doc4.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,450 Underlying: Common Stock · 11,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,134 | $24.28 | $76,093.52 |
DisclosureSEC source: 0001209191-22-030067 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,894 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.17 to $24.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,866 | $23.76 | $186,896.16 |
DisclosureSEC source: 0001209191-22-030067 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707,028 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $23.17 to $24.16. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.